597 related articles for article (PubMed ID: 19627167)
1. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
2. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
3. Mecasermin rinfabate.
Kemp SF
Drugs Today (Barc); 2007 Mar; 43(3):149-55. PubMed ID: 17380212
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mecasermin rinfabate.
Kemp SF; Fowlkes JL; Thrailkill KM
Expert Opin Biol Ther; 2006 May; 6(5):533-8. PubMed ID: 16610982
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
Tonella P; Flück CE; Mullis PE
Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
[TBL] [Abstract][Full Text] [Related]
7. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
[TBL] [Abstract][Full Text] [Related]
9. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Williams RM; McDonald A; O'Savage M; Dunger DB
Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):311-24. PubMed ID: 18363546
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
11. Investigational agents for the treatment of growth hormone-insensitivity syndrome.
Kemp SF; Thrailkill KM
Expert Opin Investig Drugs; 2006 Apr; 15(4):409-15. PubMed ID: 16548790
[TBL] [Abstract][Full Text] [Related]
12. Mecasermin.
Keating GM
BioDrugs; 2008; 22(3):177-88. PubMed ID: 18481900
[TBL] [Abstract][Full Text] [Related]
13. Recombinant IGF-I: Past, present and future.
Bright GM
Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
[TBL] [Abstract][Full Text] [Related]
14. SomatoKine: is there a use in treating growth disorders?
Kemp SF; Thrailkill KM
Curr Opin Investig Drugs; 2005 Apr; 6(4):373-7. PubMed ID: 15898344
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
16. The role of recombinant human insulin-like growth factor-I in treating children with short stature.
Collett-Solberg PF; Misra M;
J Clin Endocrinol Metab; 2008 Jan; 93(1):10-8. PubMed ID: 18165284
[TBL] [Abstract][Full Text] [Related]
17. Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency.
Backeljauw P
Growth Horm IGF Res; 2020 Apr; 51():22-26. PubMed ID: 31982729
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
Richmond EJ; Rogol AD
Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
[TBL] [Abstract][Full Text] [Related]
19. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-I alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth.
Ekström K; Carlsson-Skwirut C; Ritzén EM; Bang P
Horm Res Paediatr; 2011; 76(5):355-66. PubMed ID: 21968387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
